Abstract
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 425-443 |
| Number of pages | 19 |
| Journal | Clinics in Liver Disease |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| State | Published - May 2008 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hepatology
Cite this
Treatment of Primary Biliary Cirrhosis : Therapy with Choleretic and Immunosuppressive Agents. / Silveira, Marina G.; Lindor, Keith.
In: Clinics in Liver Disease, Vol. 12, No. 2, 05.2008, p. 425-443.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of Primary Biliary Cirrhosis
T2 - Therapy with Choleretic and Immunosuppressive Agents
AU - Silveira, Marina G.
AU - Lindor, Keith
PY - 2008/5
Y1 - 2008/5
N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.
AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.
UR - http://www.scopus.com/inward/record.url?scp=43049083346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43049083346&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2008.02.008
DO - 10.1016/j.cld.2008.02.008
M3 - Article
C2 - 18456189
AN - SCOPUS:43049083346
VL - 12
SP - 425
EP - 443
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
SN - 1089-3261
IS - 2
ER -